Opening setting
71%No trades yet. This is the uniform opening setting, not a community forecast.
Probability that the predicted event happens at all: all yes / by-a-date outcomes added together. “Other” is tracked as its own third slice.
Outcomes
Resolution criteria
The first dosed patient in a registered NewLimit study. Resolution horizon: 2030-12-31. Source: NewLimit, ClinicalTrials.gov.
Evidence & context
Trials, publications and reports our research found on this prognosis. Each links to the original source.
This is a NewLimit company blog post announcing a Series C financing and stating the company is bringing its first aging reprogramming medicine to human clinical trials. It is directly relevant because it signals management's expected timeline toward first-in-human studies, which bears on when a first patient might be dosed in a registered trial.
This is a NewLimit blog post by Jacob C. Kimmel summarizing 2025 progress. It states NewLimit began developing its first medicines ahead of schedule in 2025 and had built its first preclinical candidate, which is relevant because it indicates the company is still in preclinical development rather than reporting a registered study with a first patient dosed.
This is a June 4, 2026 news report stating NewLimit raised $435 million to fund its first human clinical trial of a cell age reprogramming therapy. It is relevant because it indicates the company is preparing for initial clinical entry, which bears on the expected timing of first patient dosing, even though it does not report a registered trial or an actual dosing event.
This is a secondary research profile on NewLimit that discusses the company’s therapeutic approach, development stage, and competitive landscape. It bears on the prognosis because it indicates NewLimit is still preclinical and does not report any registered study or patient dosing yet.
This appears to be a LinkedIn post amplifying BioSpace coverage about NewLimit's fundraising and development status. It is relevant because it indicates NewLimit was still pre-clinical and positioning the new funding as support for the path to human trials, which bears indirectly on when a first patient might be dosed.